Advertisement

Picture Fairtec GmbH Worldwide Event Solutions 600x60px
Document › Details

Adrenomed AG. (5/6/19). "Press Release: Adrenomed AG Takes Part in Three Upcoming Conferences". Hennigsdorf.

Region Region Barcelona
  Country Spain (España)
Organisations Organisation Adrenomed AG
  Organisation 2 BIO (US) (Biotechnology Innovation Organization, formerly Biotechnology Industry Organization)
Products Product BioEquity Europe 2019 Barcelona
  Product 2 BIO 2019 Philadelphia (BIO International Convention)
Index terms Index term Adrenomed–Informa: investor conference, 201905 supply service Adrenomed presents at BioEquity Europe 2019 in Barcelona
  Index term 2 Adrenomed–BIO (US): partnering conference, 201906 supply service Adrenomed presents at BIO International Convention
Persons Person Hein, Frauke (Deutsche Biotech Innovativ 201211 Managing Director of MLDx GmbH + Adrenomed)
  Person 2 Bauer, Eva (MC Services 201811)
     


Adrenomed AG, the vascular integrity company, announced today its participation at three upcoming conferences in Europe and the USA. Adrenomed representatives will be available for one-on-one meetings at the following events:

Swiss Biotech Day 2019 and Annual General Assembly of the Swiss Biotech Association
May 07, 2019, Congress Center, Basel, Switzerland
https://swissbiotechday.ch/home/

20th Annual Bio€quity Europe
May 20 – 21, 2019, Crowne Plaza Barcelona Fira Center, Barcelona, Spain
Dr. Frauke Hein, Chief Business Officer of Adrenomed, will give a company presentation on May 20, 16:30 CET, room Rossini 2.
https://www.biocentury.com/conferences/bio€quity-europe-2019

BIO International Convention 2019
June 3 – 6, 2019, Pennsylvania Convention Center, Philadelphia (PA), USA
Dr. Frauke Hein, Chief Business Officer of Adrenomed, will represent the company and give a presentation.
https://convention.bio.org/


About Adrenomed

Adrenomed AG is a German privately-financed, clinical stage biopharmaceutical company. Adrenomed´s mission is to rescue vascular integrity in order to save the lives of critically ill patients with limited treatment options. Founded in 2009 by a management team with decades of in-depth experience in sepsis and deep knowledge in diagnostics and drug development, the Company’s lead product candidate Adrecizumab is a clinical-stage, first-in-class monoclonal antibody. Adrecizumab targets the vasoprotective peptide Adrenomedullin, an essential regulator of vascular integrity. Adrecizumab is currently under clinical evaluation in a biomarker-guided, double-blinded, placebo-controlled, randomized, multicenter proof-of-concept Phase II study with 300 patients suffering septic shock. Excellent safety and tolerability were demonstrated in two Phase I trials.


Contact

Adrenomed AG
Frauke Hein, Ph.D. (Chief Business Officer)
phone: +49 (0)3302 2077814
fhein@adrenomed.com

Media Inquiries
MC Services AG
Eva Bauer/Julia von Hummel
phone: +49 (0)89 21022880
adrenomed@mc-services.eu

   
Record changed: 2019-05-15

Advertisement

Picture [LSUS] Life-Sciences-USA.com – The Business Web Portal 600x60px

More documents for Adrenomed AG


To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE Newsletter«

To get even more information, please take a look at our [gs] professional services offering and read the gene-sensor Product Flyer [PDF file]

Advertisement

Picture [LSUK] Life-Sciences-UK.com – The Business Web Portal 600x80px




» top